Avoidable drug-gene conflicts and polypharmacy interactions in patients participating in a personalized medicine program

作者：Reynolds Kristen K^*; Pierce Deanne L; Weitendorf Frederick; Linder Mark W

来源：Personalized Medicine, 2017, 14(3): 221-233.

DOI：10.2217/pme-2016-0095

• adverse drug reactions
• drug-drug interactions
• drug-gene conflicts
• medication sensitivity
• pharmacogenetics
• polypharmacy
• precision medicine

Aim: Determine the ability of a pharmacogenetic service, PRIMER, to identify drug-gene (DGI) and drug-drug interactions (DDI) in patients across multiple conditions. PRIMER consists of patient selection criteria, a gene panel and actionable guidance for DGIs and DDIs. Results: The average patient was prescribed 12 medications. PRIMER identified significant DGIs in 73% of patients tested, with 43% having more than one DGI. DDIs were found in 87% of patients. The most common actionable DGIs were for opioid, psychotropic and cardiovascular medications. Conclusion: The pairing of patient selection criteria, a multigene panel with evidence-based interpretation and review of DDIs maximizes the patients tested who have actionable benefit and alerts physicians to potentially critical adjustments needed for the patient's medication regimen.

• 出版日期2017-5